Professor Philip S. Low
Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low has spent more than 45 years doing pioneering work in the fields of tissue regeneration, infectious diseases, erythrocyte membranes and auto-immune diseases. He has published more than 500 articles and has 500 patents/patents pending. Dr. Low is the co-founder of three RBP portfolio companies: Novosteo, Eradivir, and MorphImmune.
Professor Philip S. Low
Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low has spent more than 45 years doing pioneering work in the fields of tissue regeneration, infectious diseases, erythrocyte membranes and auto-immune diseases. He has published more than 500 articles and has 500 patents/patents pending. Dr. Low is the co-founder of three RBP portfolio companies: Novosteo, Eradivir, and MorphImmune.
Academic Appointment(s)
- Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, Purdue University
Educational Background
- Brigham Young University, B.S. Chemistry, 1971
- University of California San Diego, Ph.D. Biochemistry, 1975
Recent Publications
- Standardization and optimization of intraoperative molecular imaging for identifying primary pulmonary adenocarcinomas. Predina, J.D., Okusanya, O., Newton, A.D., Low, PS and Singhal, S. Molecular Imaging and Biology. 20(1), pp.131-138 (2018)
- Imaging and Methotrexate Response Monitoring of Systemic Inflammation in Arthritic Rats Employing the Macrophage PET Tracer [18F]Fluoro-PEG-Folate. Chandrupatla DMSH, Jansen G, Mantel E, Low PS, Matsuyama T, Musters RP, Windhorst AD, Lammertsma AA, Molthoff CFM, van der Laken CJ1. Contrast Media Mol Imaging 10:1155 (2018)
- Fluorescence-guided surgery of cancer: applications, tools and perspectives. Low PS, Singhal S, Srinivasarao M. Curr Opin Chem Biol. 45:64-72 (2018)
- An open label trial of folate receptor-targeted intraoperative molecular imaging to localize pulmonary squamous cell carcinomas. Predina JD, Newton AD, Xia L, Corbett C, Connolly C, Shin M, Sulyok LF, Litzky L, Deshpande C, Nie S, Kularatne SA, Low PS, Singhal S. Oncotarget. 9:13517-13529 (2018)
- Synthesis and Evaluation of a Novel 64Cu- and 67Ga-Labeled Neurokinin 1 Receptor Antagonist for in Vivo Targeting of NK1R-Positive Tumor Xenografts. Zhang H, Kanduluru AK, Desai P, Ahad A, Carlin S, Tandon N, Weber WA, Low PS. Bioconjug Chem. 10.1021 (2018)
- New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K+/H+ Exchange. Rangasamy L, Chelvam V, Kanduluru AK, Srinivasarao M, Bandara NA, You F, Orellana EA, Kasinski AL, Low PS. Bioconjug Chem. 10.1021 (2018)
- Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. Shen J, Hu Y, Putt KS, Singhal S, Han H, Visscher DW, Murphy LM, Low PS. Oncotarget. 9:4485-4495 (2017)
- Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. Boogerd LSF, Hoogstins CES, Gaarenstroom KN, de Kroon CD, Beltman JJ, Bosse T, Stelloo E, Vuyk J, Low PS, Burggraaf J, Vahrmeijer AL. Oncotarget. 9: 791-801 (2017)
- Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases. Poh S, Chelvam V, Ayala-López W, Putt KS, Low PS. Nanomedicine. 14:1033-1043 (2018)
- A Phase I Clinical Trial of Targeted Intraoperative Molecular Imaging for Pulmonary Adenocarcinomas. Predina JD, Newton AD, Keating J, Dunbar A, Connolly C, Baldassari M, Mizelle J, Xia L, Deshpande C, Kucharczuk J, Low PS, Singhal S. Ann Thorac Surg. 105:901-908 (2018)
In The News
- Research Bridge Partners Makes Seed Capital Investment In Novosteo, Inc.
- Successful Purdue entrepreneurs provide targeted advice to faculty and staff entrepreneurs entering startup world
- Purdue startup sold in $2.1B pharma deal
- Purdue startup Endocyte sold in $2.1B deal with pharmaceutical giant Novartis
- $2.1B Endocyte Deal a Record-Breaker
- Great Minds Talk Cancer
- $1.7 million SBIR grant fast-tracks faster bone fracture healing
